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Purpose: To evaluate the effect of baseline subretinal ﬂuid (SRF) on treatment outcomes with intravitreal
aﬂibercept injection (IAI) versus laser treatment in patients with diabetic macular edema (DME) in the VIVID and
VISTA studies.
Design: Post hoc analysis of 2 randomized controlled trials.
Participants: Eight hundred seventy-two patients with DME.
Methods: We randomized patients to receive IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5
monthly doses (2q8), or laser.
Main Outcome Measures: Effect of presence or absence of baseline SRF on visual outcomes in the inte-
grated dataset at weeks 52 and 100.
Results: Mean best-corrected visual acuity (BCVA) gains in the 2q4, 2q8, and laser arms at week 52
were þ14.5, þ11.0, and e2.3 letters, respectively, (those with baseline SRF) and þ10.3, þ10.6, and þ2.5 letters,
respectively, (those without). At week 100, mean gains were þ13.5, þ10.9, and 2.3 letters (those with baseline
SRF) and þ10.6, þ10.0, and þ2.7 letters (those without). The treatment effect for IAI versus laser from baseline to
week 52 of 100 was greater for patients with baseline SRF versus those without (nominal P < 0.001, for inter-
action). The proportions of patients who gained 15 letters or more in the 2q4, 2q8, and laser arms at week 52 were
52.3%, 40.2%, and 8.9%, respectively, (those with baseline SRF) and 30.9%, 29.1%, and 8.2%, respectively,
(those without) and at week 100 were 50.0%, 35.4%, and 12.9%, respectively, (those with baseline SRF) and
33.3%, 30.5%, and 12.5%, respectively, (those without). Time to ﬁrst sustained SRF clearance seemed to be
shorter in the IAI arms versus laser. The overall safety proﬁle was similar in the IAI arms.
Conclusions: This post hoc analysis demonstrated the visual outcome beneﬁts of IAI over laser, regardless
of baseline SRF status. A greater treatment effect of IAI was observed in patients with baseline SRF versus those
without; however, no meaningful impact of baseline SRF status on treatment outcomes with IAI was demon-
strated, indicating that the differential effects of laser might have been the driving force behind the different
treatment outcomes in both groups. Ophthalmology Retina 2019;3:663-669 ª 2019 by the American Academy of
Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).With the increasing prevalence of diabetes worldwide, the
ocular complications of this disease, including diabetic
macular edema (DME) also have become much more
common.1e6 Current treatment options for DME include
macular laser, corticosteroids,7 and intravitreal injections of
antievascular endothelial growth factor (VEGF) agents (i.e.,
aﬂibercept, ranibizumab, and off-label bevacizumab).
Antievascular endothelial growth factor agents now are
recognized as the treatment of choice in patients with DME
compared with previous standards of care.8e12 Intravitreal
aﬂibercept injections (IAIs) consist of a recombinant fusion
protein that currently is indicated for the treatment of neo-
vascular (wet) age-related macular degeneration, macular
edema after retinal vein occlusion, myopic choroidal neo-
vascularization, and DME.13 The VIVID-DME and VISTA-
DME studies have shown that IAI is safe and is associated 2019 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.with superior visual and anatomic outcomes compared with
laser monotherapy.14
Vascular endothelial growth factor induces vascular
hyperpermeability and extravasation of blood proteins into
the tissues, and subretinal ﬂuid (SRF) is correlated signiﬁ-
cantly with intraocular VEGF concentrations.15 The
correlation between the presence or absence of baseline
SRF and treatment outcomes with anti-VEGF agents has
not been studied directly; however, a subanalysis of RISE
(A Study of Ranibizumab Injection in Subjects with Clini-
cally Signiﬁcant Macular Edema with Center Involvement
Secondary to Diabetes Mellitus) and RIDE (A Study of
Ranibizumab Injection in Subjects with Clinically Signiﬁ-
cant Macular Edema with Center Involvement Secondary to
Diabetes Mellitus) trials assessing the correlation between
baseline SRF and treatment outcomes with ranibizumab in663https://doi.org/10.1016/j.oret.2019.03.015
ISSN 2468-6530/19
Ophthalmology Retina Volume 3, Number 8, August 2019patients with DME indicated that the presence of baseline
SRF is a good predictor for treatment outcomes, including
improvement in visual acuity and resolution of macular
edema in patients treated with ranibizumab.16 Furthermore,
a subanalysis of the ranibizumab study READ-3
(Ranibizumab for Edema of the Macula in Diabetes
Protocol 3 with High Dose), found that patients with SRF
at baseline showed statistically signiﬁcant greater visual
gains than those without baseline SRF.17 In this post hoc
analysis of the VIVID and VISTA studies, we aimed to
evaluate the impact of the presence (or absence) of
baseline SRF on treatment outcomes with IAI, as well as
the treatment effect of IAI versus laser therapy, in patients
with DME.
Methods
Study Design
The VIVID (ClinicalTrials.gov identiﬁer, NCT01331681) and
VISTA (ClinicalTrials.gov identiﬁer, NCT01363440) study de-
signs and methods have been published previously14; key details
are summarized here. The VIVID and VISTA studies were 2
similarly designed, phase 3, randomized, double-masked, active-
controlled, 148-week trials comparing 2 dosing regimens of IAI
with laser control for the treatment of DME. The studies were
conducted at 127 sites across Australia, Europe, Japan, and the
United States, in accordance with the tenets of the Declaration of
Helsinki and with the International Conference on Harmonisation
guidelines. Institutional review board or ethics committee approval
was obtained at each site before the start of the studies. All patients
provided written informed consent.
Adult patients with type 1 or 2 diabetes mellitus who demon-
strated DME with central involvement (deﬁned as retinal thick-
ening involving the central 1-mm central subﬁeld thickness) were
included if best-corrected visual acuity (BCVA) was between 73
and 24 letters (Snellen equivalent, 20/40e20/320) in the study eye.
Only 1 eye per patient was included in the study. Patients were
randomized 1:1:1 to receive IAI 2 mg every 4 weeks (2q4), IAI 2
mg every 8 weeks after 5 initial monthly doses (2q8), or macular
laser photocoagulation at baseline. Beginning at week 12, when the
laser retreatment criteria were met, study eyes in groups 1 and 2
received sham laser and those in group 3 received active laser, but
not more frequently than every 12 weeks. From week 24, addi-
tional active treatment (laser in the IAI groups and IAI in the laser
control group) was allowed as rescue treatment in cases of disease
recurrence or worsening based on prespeciﬁed criteria. Patients in
the laser control treatment group were eligible to receive IAI
treatment in the third year; therefore, we included only data from
weeks 52 and 100 in this post hoc analysis.
Outcome Measures
The primary efﬁcacy end point for the VIVID and VISTA studies
was the change from baseline BCVA in Early Treatment Diabetic
Retinopathy Study (ETDRS) letters at week 52.14 In our post hoc
analysis, we investigated the effect of baseline SRF status (patients
with SRF at baseline and patients without SRF at baseline) on
treatment outcomes in patients with DME. We integrated data
from VIVID and VISTA and examined outcomes at weeks 52
and 100. To determine baseline SRF status, OCT images were
evaluated at independent central reading centers (Duke Reading
Center, Durham, NC, for VISTA; Vienna Reading Center,
Vienna, Austria, for VIVID).664Efﬁcacy end points evaluated in this post hoc analysis include
the mean change in BCVA (ETDRS letters) from baseline by
baseline SRF status and the treatment effect of IAI versus laser
therapy (after adjustment for baseline vision) by baseline SRF
status (with vs. without SRF), which was measured by analyzing
the BCVA ETDRS letter score. The proportion of patients who
gained 15 letters or more in BCVA by baseline SRF status also was
evaluated. The corresponding treatment effect of IAI (after
adjustment for baseline vision) by baseline SRF status was
measured by analyzing the proportion of patients with a 15-letter or
more gain from baseline in BCVA. We also assessed the time to
ﬁrst sustained SRF clearance (deﬁned as time to ﬁrst 2 consecutive
readings of no SRF after a reading of SRF at baseline).
Statistical Analysis
Patients included in the full analysis sets (all randomized patients
who received any studymedication and underwent at least 1 baseline
and 1 postbaseline assessment) of the VIVID and VISTA studies
were included in the current efﬁcacy analysis.We used an analysis of
covariance model to analyze the treatment effect of IAI over laser
therapy; baseline visual acuity, treatment, study, baseline SRF sta-
tus, and the interaction between baseline SRF status and treatment
were included as ﬁxed effects. For analysis of the proportion of
patients who gained 15 letters or more from baseline at weeks 52 and
100 as stratiﬁed by baseline SRF status, we used estimated odds
ratios based on a logistic regression model; baseline visual acuity,
treatment, study, baseline SRF status, and the interaction between
baseline SRF status and treatment were included as ﬁxed effects. For
time to ﬁrst sustained SRF clearance analysis, we used observed
cases before dropout or additional treatment, without further impu-
tation for missing values. Patients were censored at the last available
visit if no 2 consecutive readings of no SRF after the baseline were
observed, whereas those who demonstrated 2 consecutive readings
of no SRF after baseline were considered to have an event with time
recorded from randomization to the ﬁrst visit of the 2 consecutive
readings of SRF after baseline. With the exception of time to ﬁrst
sustained SRF clearance, missing values were imputed using the last
observation carried forward method for all other analyses. For eyes
that received additional (rescue) treatment, the last value before
additional treatment was carried forward was used. Patients with
missing SRF status at baseline were excluded from the SRF sub-
group analyses. All analyses with nominal P values were performed
in an ad hoc fashion without formal multiplicity adjustment. Results
may be interpreted as exploratory and hypothesis generating.Results
In the VIVID and VISTA studies, mean BCVA gains from baseline
were greater in the 2q4 and 2q8 arms compared with laser at both
week 52 and 100; in addition, a greater proportion of eyes in the
IAI groups gained 15 letters or more compared with eyes in the
laser control group at both time points.14
Post Hoc Analysis
The number of patients demonstrating SRF at baseline in the 2q4,
2q8, and laser arms were 86, 82, and 101, respectively. The cor-
responding number of patients not demonstrating SRF at baseline
were 204, 203, and 184, respectively (Table 1). Mean baseline
BCVA was slightly lower in the SRF at baseline group
compared with the no SRF at baseline group across all treatment
arms (Fig 1; Table 1).
Table 1. Mean Change in Best-Corrected Visual Acuity in Patients with and without Baseline Subretinal Fluid at Weeks 52 and 100*
Treatment Groups
Laser Control
Intravitreal Aﬂibercept
2 mg Every 4 Weeks
Intravitreal Aﬂibercept
2 mg Every 8 Weeks
Intravitreal Aﬂibercept 2 mg
Every 4 Weeks
vs. Laser Therapy,y
Least-Squares Mean
(Standard Error)
Treatment Difference
(95% Conﬁdence
Interval)
Intravitreal Aﬂibercept
2 mg Every 8 Weeks vs.
Laser Therapy,y
Least-Squares Mean
(Standard Error)
Treatment Difference (95%
Conﬁdence Interval)
With baseline SRF n ¼ 101 n ¼ 86 n ¼ 82
Mean baseline
BCVA
59.8 57.6 58.2 d d
Time points Week 52 Week 100 Week 52 Week 100 Week 52 Week 100 Week 52 Week 100 Week 52 Week 100
Mean change in
BCVA (SD),
ETDRS letters
e2.3 (13.3) e2.3 (14.5) 14.5 (10.5) 13.5 (15.1) 11.0 (9.3) 10.9 (11.5) 16.45 (13.48e19.41);
P < 0.001
15.52 (11.91e19.14);
P < 0.001
13.07 (10.18e15.96);
P < 0.001
13.02 (9.67e16.38);
P < 0.001
Without baseline SRF n ¼ 184 n ¼ 204 n ¼ 203
Mean baseline
BCVA
60.4 60.7 59.5 d d
Time points Week 52 Week 100 Week 52 Week 100 Week 52 Week 100 Week 52 Week 100 Week 52 Week 100
Mean change in
BCVA (SD),
ETDRS letters
2.5 (10.1) 2.7 (11.5) 10.3 (8.9) 10.6 (11.3) 10.6 (8.5) 10.0 (10.3) 7.85 (5.78e9.93);
P < 0.001
7.96 (5.46e10.47);
P < 0.001
7.96 (5.94e9.99);
P < 0.001
7.18 (4.84e9.51);
P < 0.001
e ¼ not available; BCVA ¼ best-corrected visual acuity; ETDRS ¼ Early Treatment Diabetic Retinopathy Study; SD ¼ standard deviation; SRF ¼ subretinal ﬂuid.
Patients for whom no baseline assessment of SRF status was available were excluded.
*Integrated data from VIVID and VISTA studies (last observation carried forward, full analysis set).
yThe difference in mean change in BCVA in ETDRS letters between the intravitreal aﬂibercept 2 mg every 4 weeks or 2 mg every 8 weeks groups and the laser therapy group, based on an analysis of
covariance model, with baseline visual acuity, treatment, baseline SRF, treatment and baseline SRF interaction, and study as ﬁxed effects.
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Figure 1. Graphs showing mean change in best-corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study [ETDRS] letter score) from
baseline (BL) to weeks 52 and 100 for patients (A) with baseline subretinal ﬂuid and (B) without baseline subretinal ﬂuid, last observation carried forward
(full analysis set population, VIVID and VISTA combined). Patients who missed SRF status at baseline were excluded. 2q4 ¼ 2-mg intravitreal aﬂibercept
injection every 4 weeks; 2q8 ¼ 2-mg intravitreal aﬂibercept injection every 8 weeks after receiving 5 initial monthly doses of intravitreal aﬂibercept.
Ophthalmology Retina Volume 3, Number 8, August 2019At week 52, the mean gain in BCVA was greater among pa-
tients in the 2q4 and 2q8 arms compared with those in the laser
arm, regardless of baseline SRF status (Fig 1; Table 1), which was
sustained through week 100 (Fig 1; Table 1). Mean gains in BCVA
in the 2q4, 2q8, and laser arms at week 52 were þ14.5
letters, þ11.0 letters, and e2.3 letters, respectively, for the SRF
at baseline group and þ10.3 letters, þ10.6 letters, and þ2.5
letters, respectively, for the no SRF at baseline group. At week
100, mean gains were þ13.5 letters, þ10.9 letters, and e2.3
letters, respectively, for the SRF at baseline group and þ10.6
letters, þ10.0 letters, and þ2.7 letters, respectively, for the no
SRF at baseline group.666The treatment effect for 2q4 and 2q8 versus laser (mean change
in ETDRS letter score from baseline to weeks 52 and 100) seemed
to be greater for patients with SRF at baseline than for those with
no SRF at baseline (Table 1; nominal P < 0.0001 for interaction at
week 52 for 2q4 and 0.0046 for 2q8; nominal P < 0.0008 for
interaction at week 100 for 2q4 and 0.0051 for 2q8 [not included
in Table 1]) when adjusted for baseline BCVA.
Likewise, a greater proportion of patients in the 2q4 and 2q8
groups gained 15 ETDRS letters or more at weeks 52 and 100 than
those treated with laser therapy, regardless of baseline SRF status
(Table 2); a numerically greater treatment effect for the IAI groups
versus the laser group was observed in the SRF at baseline group
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Korobelnik et al  Baseline SRF Effect on Outcomes in DMEversus the no SRF at baseline group. The proportion of patients
who gained 15 letters or more in the 2q4, 2q8, and laser arms at
week 52 was 52.3%, 40.2%, and 8.9%, respectively, for the SRF
at baseline group and 30.9%, 29.1%, and 8.2%, respectively, for
the no SRF at baseline group. At week 100, the proportion of
patients who gained 15 letters or more was 50.0%, 35.4%, and
12.9%, respectively, for the SRF at baseline group and 33.3%,
30.5%, and 12.5%, respectively, for the no SRF at baseline group.
With respect to patients who gained 15 letters or more from
baseline at weeks 52 and 100, this ad hoc data indicated no clear
signiﬁcance that baseline SRF affects treatment outcomes in
patients receiving 2q4 or 2q8 compared with laser (nominal P ¼
0.14 and P ¼ 0.45 for week 52 and P ¼ 0.19 and P ¼ 0.70 for
week 100 for 2q4 and 2q8, respectively). At both time points
(weeks 52 and 100), patients with SRF at baseline in the 2q4 and
2q8 arms showed a numerically greater chance of gaining 15 letters
or more from baseline than those with no SRF at baseline when
compared with the laser therapy group (Table 2).
All but 1 patient with SRF at baseline (98.8%) in the 2q4 arm
and all but 3 such patients (96.3%) in the 2q8 arm showed at least 2
consecutive negative SRF readings (i.e., sustained SRF clearance),
compared with 80.2% of patients in the laser group who ever
experienced sustained SRF clearance (Fig 2).
In the SRF at baseline group, the time to ﬁrst sustained SRF
clearance seemed to be shorter in the 2q4 arm (median, 1.86
months; 95% conﬁdence interval, 0.95e1.87 months) and 2q8 arm
(median, 1.12 months; 95% conﬁdence interval, 0.95e1.87
months) compared with the laser arm (median, 4.63 months; 95%
conﬁdence interval, 3.71e6.44 months; Fig 2).
The overall incidence of ocular and nonocular serious adverse
events was similar across treatment groups in VIVID and VISTA.
The most frequent ocular serious adverse event was cataract (3.1%,
2.1%, and 0.3% for the 2q4, 2q8, and laser arms, respectively).14Discussion
In this post hoc analysis, we investigated the impact of
baseline SRF status on treatment outcomes in patients
enrolled in the VIVID and VISTA studies. Compared with
the laser control group, the mean gain in BCVA was greater
among patients treated with IAI, regardless of baseline SRF
status. Similarly, regardless of baseline SRF status, patients
in the IAI groups were more likely to achieve a 15-letter or
more gain in BCVA while experiencing shorter times to ﬁrst
sustained SRF clearance than patients treated with laser
therapy.
When looking at the change in BCVA at weeks 52 and
100 in patients stratiﬁed by baseline SRF status, the treat-
ment effect of IAI over laser therapy was greater in patients
with SRF at baseline. This difference in treatment effect at
least in part was driven by a greater improvement in BCVA
from baseline in laser-treated patients in the no SRF at
baseline group compared with the SRF at baseline group
(approximately 5-letter difference).
The presence of SRF is considered an indicator of disease
activity and is known to have a negative effect on visual
function.16,18 Treatment with anti-VEGF agents reduces
retinal ﬂuid volume and improves visual function.16,19 A
post hoc analysis of RISE and RIDE trials of ranibizumab667
Figure 2. Kaplan-Meier plot showing time to ﬁrst sustained subretinal ﬂuid (SRF) clearance* for patients with baseline SRF, observed case (full analysis set
population, VIVID and VISTA combined). *First sustained SRF clearance is deﬁned as time to ﬁrst 2 consecutive negative SRF readings after a baseline
positive SRF reading. 2q4 ¼ 2-mg intravitreal aﬂibercept injection every 4 weeks; 2q8 ¼ 2-mg intravitreal aﬂibercept injection every 8 weeks after receiving
5 initial monthly doses of intravitreal aﬂibercept.
Ophthalmology Retina Volume 3, Number 8, August 2019for the treatment of DME and a retrospective, observational,
cohort study of patients with dexamethasone implants
indicated that the presence of baseline SRF was predictive
for better visual outcomes compared with those without
baseline SRF.16,20 Although our analysis indicates that the
gain in BCVA with IAI treatment was similar across the
groups with and without SRF at baseline, the treatment ef-
fect of IAI versus laser therapy seemed to be greater in the
group with SRF at baseline, although mean baseline visual
acuity was slightly lower in the SRF at baseline group than
in the no SRF at baseline group.
A key limitation of our study is that it was a post hoc
analysis rather than a prespeciﬁed subgroup analysis.
However, the randomized design, ﬁxed dosing, and strict
protocols of the VIVID and VISTA studies constitute the
strengths of this analysis.
Although the role of SRF as a predictive factor in DME
remains to be elucidated fully, this post hoc analysis
demonstrated the visual outcome beneﬁts of IAI over laser,
regardless of baseline SRF status. Results from the sustained
SRF resolution analysis of patients with baseline SRF also
supported the anatomic ﬁndings, along with the beneﬁts of
IAI over laser seen in functional outcomes. Our understand-
ing of the relationship between ﬂuid status and visual acuity
outcomes continues to evolve; however, overall, these ﬁnd-
ings suggest that patients with and without baseline SRF can
achieve greater visual gains with IAI treatment compared
with laser therapy.References
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